NDAOPHTHALMICGEL
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
LOTEMAX (loteprednol etabonate) by Bausch + Lomb is healing. Approved for ocular inflammation, inflammation, post-operative pain and inflammation and 2 more indications. First approved in 2012.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTEMAX (loteprednol etabonate) is an ophthalmic corticosteroid gel approved in 2012 that inhibits inflammatory responses by suppressing prostaglandin production and blocking edema, leukocyte migration, and scar formation. It is indicated for ocular inflammation, post-operative pain and inflammation following cataract surgery, and allergic conjunctivitis. The drug undergoes rapid metabolism to inactive metabolites with minimal systemic absorption.
Peak
LOTEMAX is at peak lifecycle stage with moderate competitive pressure (30/100), indicating a mature, stable market with established sales infrastructure.
Mechanism of Action
healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid…
Indications (5)
Worked on LOTEMAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.